{"filings":[{"id":94055,"accession_number":"0001606498-26-000061","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical announces Q1 2026 results; filing includes no financial figures","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued May 5, 2026 covering three months ended March 31, 2026.","No specific revenue, EPS, or segment data available in the filing excerpt.","Investors should refer to the full press release for detailed results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":182200000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94054,"accession_number":"0001606498-26-000046","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Avanos Medical to be acquired by AIP for $25/share, $1.272B enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Avanos stockholders receive $25.00 per share in cash; enterprise value approx. $1.272B.","Premium of 72.1% to April 13 closing price and 82.8% to 30-day VWAP.","Acquisition unanimously approved by Avanos Board; expected to close H2 2026.","Closing conditions include stockholder approval and HSR clearance; no financing condition.","Avanos common stock will be delisted from NYSE; 2026 annual meeting postponed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106139,"accession_number":"0001606498-26-000017","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avnos Medical raises CEO David Pacitti's annual LTIP target to $5.5M from $5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board increased CEO David Pacitti's annual LTIP target from $5M to $5.5M.","The change is effective for 2026 under the 2021 Long Term Incentive Plan.","The $500k increase represents a 10% rise in target value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106138,"accession_number":"0001606498-26-000007","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Avanos adds two directors in cooperation deal with activist Radoff","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Cunniff (CEO of Electromed) and William Burke (former EVP/CFO Haemonetics) nominated for board at 2026 annual meeting.","Bradley Radoff withdraws his director nomination and agrees to standstill and voting commitments through early 2027.","Agreement resolves potential proxy contest; Radoff expresses confidence in new directors and Avanos' future.","Board chair says Cunniff and Burke bring complementary operating and financial expertise to support strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106137,"accession_number":"0001606498-26-000002","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.","Q4 GAAP net loss $1.3M ($0.03 loss per share); adjusted net income $13.4M ($0.29 adjusted EPS).","Full-year 2025 net loss $72.9M; adjusted EBITDA $86.8M vs $107.6M in 2024.","Recorded $77M non-cash goodwill impairment on PM&R segment in Q2 2025.","2026 guidance: net sales $700-720M; adjusted diluted EPS $0.90-1.10."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":701200000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106136,"accession_number":"0001628280-26-001991","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos Medical presents at JP Morgan Healthcare Conference; no material financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dave Pacitti presented company strategy at JP Morgan Healthcare Conference on January 13, 2026.","No specific financial guidance, earnings numbers, or material new initiatives were provided in the exhibited slide deck.","The presentation primarily consisted of forward-looking statements and general business direction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122428,"accession_number":"0001606498-25-000135","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos eliminates CCO and GC roles; final severance includes full vesting of James's 16,300 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company eliminated Chief Commercial Officer and General Counsel positions effective Dec 1, 2025 as part of restructuring.","Kerr Holbrook (CCO) and Mojirade James (GC) terminated; responsibilities reallocated.","Severance: Holbrook $1,535,417; James $1,425,665; plus COBRA, prorated bonuses, equity vesting.","16,300 time-based RSUs granted to James on April 22, 2025 vested fully on Dec 1, 2025.","Unvested awards treated as retirement; time-based PRSUs pro-rata vested, performance-based vest at end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122430,"accession_number":"0001606498-25-000129","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical files Q3 2025 earnings release; detailed results not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for three and nine months ended September 30, 2025 furnished as Exhibit 99.1.","No specific financial figures (revenue, EPS, segments) available in the filing materials submitted.","Earnings release date: November 5, 2025; coverage period Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":520300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122429,"accession_number":"0001606498-25-000126","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos eliminates Chief Commercial Officer and General Counsel positions; two executives to leave Dec 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kerr Holbrook (CCO) and Mojirade James (General Counsel & Secretary) terminated effective Dec 1, 2025 due to position elimination in restructuring.","Severance: Holbrook ~$1.54M, James ~$1.43M, plus 12 months COBRA premium coverage.","Unvested equity: time-based RSUs vest pro rata; performance-based RSUs vest at end of period; stock options exercisable for 5 years.","Prorated 2025 bonuses at target approved for both executives.","Payments conditional on separation agreement, general release, and continued compliance with confidentiality/non-solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139126,"accession_number":"0001606498-25-000123","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos Medical acquires Nexus Medical for TKO anti-reflux connector; accretive to revenue/ EPS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Nexus Medical, LLC, maker of TKO needleless connector technology for NICU/PICU.","Financed with available cash; expected to be immediately accretive to both revenue growth and EPS.","Adds complementary technology to Avanos' Specialty Nutrition Systems business.","No purchase price disclosed; target is a privately held company based in Lenexa, Kansas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139125,"accession_number":"0001606498-25-000106","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.","Adjusted EPS $0.17 vs $0.34; adjusted EBITDA $17.0M vs $26.8M YoY.","Recorded $77M goodwill impairment in PM&R segment due to market cap pressure.","Divested HA product line (TriVisc, GenVisc 850) to Channel-Markers Medical on July 31, 2025.","Appointed Scott Galovan as CFO effective Aug 1, 2025; CEO Pacitti appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":342500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156650,"accession_number":"0001606498-25-000087","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.","Net income $6.6M ($0.14 diluted EPS) vs $0.5M ($0.01) a year ago; adjusted net income $12.0M ($0.26 adjusted EPS).","SNS segment net sales $101.1M with 8.7% volume growth driven by enteral feeding and neonate solutions.","PM&R segment net sales $56.2M; RFA product sales grew 8.2% from ESENTEC/TRIDENT momentum.","2025 revenue guidance reaffirmed at $665-$685M; adjusted EPS guidance lowered to $0.75-$0.95 due to tariff impacts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":167500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156649,"accession_number":"0001606498-25-000085","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos Medical finalizes separation with Officer Greiner; $2.1M severance, accelerated RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cash severance of $2.1M plus prorated 2025 bonus based on actual performance, paid in 2026.","Immediate vesting of 44,189 TRSUs granted Oct 29, 2024 and 10,000 TRSUs granted Dec 3, 2024.","Consulting engagement as independent contractor through May 16, 2025 with $50,000 fee.","COBRA premium coverage for six months at 100% of monthly premiums.","Separation conditioned on non-revocation of release and compliance with confidentiality agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156646,"accession_number":"0001606498-25-000081","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos appoints Jason Pickett as Interim CFO; Greiner departs with $2.1M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Greiner departs after not being offered comparable role post-interim CEO; receives $2.1M severance, prorated bonus, $50K consulting fee.","Jason Pickett named Interim CFO and Treasurer effective April 14; salary $350K/year plus $30K/month stipend.","Pickett granted special $200K TRSU award with 12-month vesting on April 22.","Warren Machan transitions from Interim CFO to consultant through April 30 at $60K/month; no second bonus.","Greiner's 54,189 special TRSUs vest immediately; all other unvested equity forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156648,"accession_number":"0001606498-25-000078","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avanos shareholders approve all proposals at 2025 annual meeting, including 2.25M share increase for LTIP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 85.8% to 90.3% of votes cast; broker non-votes excluded.","Deloitte & Touche ratified as auditor for 2025 with 94.7% of votes cast in favor.","Say-on-pay advisory vote passed with 86.7% of votes cast for, 11.4% against.","Amendment to 2021 Long Term Incentive Plan approved: 2,250,000 new shares added to reserve.","93.6% of outstanding shares represented at the meeting; high quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156647,"accession_number":"0001606498-25-000064","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos CFO transition: Greiner departs, Pickett named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Greiner leaves Avanos effective April 18, 2025; receives $2.1M severance, prorated 2025 bonus, and 6 months COBRA.","Warren Machan ends role as Interim CFO April 14; will consult at $60K/month through April 30, forfeiting $45K second bonus.","Jason Pickett, formerly VP Tax and Treasurer, appointed Interim CFO and Treasurer as of April 14.","Greiner's special equity awards (44,189 + 10,000 RSUs) vest immediately; all other unvested awards cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156645,"accession_number":"0001606498-25-000063","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos appoints David Pacitti as CEO, effective April 14, 2025; compensation disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Pacitti, former Siemens Healthineers Americas President, becomes CEO effective April 14, 2025.","Compensation: $1.05M base salary, 110% bonus target, $5M annual LTI target for 2026.","One-time equity awards: $3.5M PRSUs (stock price hurdles $20-$33) and $3.5M TRSUs (3-year vest).","Receives $500K cash sign-on; also serves on Orchestra BioMed (OBIO) board since March 2024.","Interim CEO Michael Greiner to continue until Pacitti starts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175068,"accession_number":"0001606498-25-000057","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos Medical names David Pacitti as CEO, effective April 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Pacitti appointed CEO of Avanos Medical, effective April 14, 2025.","Pacitti was President & Head of the Americas at Siemens Healthineers.","Base salary $1.05M, bonus target 110%, 2026 LTI target $5M.","One-time $500K cash sign-on and $7M in equity awards ($3.5M PRSUs + $3.5M TRSUs).","Pacitti will succeed interim CEO Michael Greiner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175067,"accession_number":"0001606498-25-000022","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q4 and FY2024 results; specific figures not available in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated February 26, 2025 for the three months and year ended December 31, 2024.","Exhibit 99.1 containing detailed financial data was referenced but not included in the provided text.","Common stock trades on NYSE under ticker AVNS."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":687800000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175066,"accession_number":"0001606498-25-000019","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos Medical at JP Morgan conference; no specific financial metrics disclosed in available text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation by Interim CEO Michael Greiner at 43rd Annual JP Morgan Healthcare Conference on January 13, 2025.","Exhibit text is truncated; only introductory remarks are visible, no numerical results or guidance provided.","No changes to previously disclosed business plans or objectives were noted in the incomplete text.","Filing is under Regulation FD; presentation is furnished, not filed, per standard practice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192021,"accession_number":"0001606498-24-000094","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos Medical formalizes Interim CFO consulting agreement with Warren Machan through May 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warren Machan appointed Interim CFO effective Oct 28, 2024; consulting agreement formalized Dec 2, 2024.","Consulting term runs through May 31, 2025; either party may terminate with 30 days' notice.","Monthly fees: $45,000 through Feb 2025, then $60,000 for Mar-May 2025; plus two $45,000 cash bonuses.","Bonuses tied to continued service through Feb 28 and May 31, 2025, and satisfactory performance as determined by CEO.","Independent contractor arrangement; no equity or employee benefits; non-solicitation for one year after term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192020,"accession_number":"0001606498-24-000089","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avanos Medical authorizes new $25M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved up to $25.0 million in common stock repurchases over one year.","Repurchases to be made at management's discretion on open market or via private transactions.","Program will not commence until at least one full trading day after release of any material non-public info.","Company is not obligated to repurchase any specific amount; program may be suspended or discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192019,"accession_number":"0001606498-24-000082","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"CEO Joseph Woody retires; CFO Michael Greiner named interim CEO; Warren Machan interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Joseph Woody retired as CEO and board member effective Oct 28, 2024; will consult through Apr 30, 2025 at $84,618/month.","Michael Greiner (SVP/CFO/CTO) appointed interim CEO; receives $600k salary, $83k/month stipend, and $1M RSU grant.","Warren Machan (former SVP Business Strategy) appointed interim CFO; compensation not yet determined.","Board will conduct a search for permanent CEO; Greiner is leading candidate but will evaluate other candidates.","Company reported Q3 2024 financial results via press release on Oct 30; specific figures not included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208493,"accession_number":"0001606498-24-000074","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q2 2024 results; filing lacks detailed financials","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Results announced for three and six months ended June 30, 2024.","No specific revenue, EPS, or segment figures available in provided text.","Guidance or outlook not mentioned in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":337800000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208492,"accession_number":"0001606498-24-000069","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos Medical appoints Indrani Franchini to Board of Directors, effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment fills a vacancy; Franchini will serve on Audit and Compliance Committees.","Compensation includes $70,000 annual cash retainer, $12,500 Audit, $7,500 Compliance, and $190,000 RSU grant.","Board now comprises 6 directors (5 independent) with 3 women, 2 ethnically diverse.","Franchini previously EVP/CLO at Alnylam, EVP/CCO at Alexion, and roles at Hess and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226186,"accession_number":"0001606498-24-000060","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos appoints Sigfrido Delgado as SVP, Integrated Supply Chain","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sigfrido (Sig) Delgado named Senior Vice President, Integrated Supply Chain, effective May 13, 2024.","Appointment announced via press release on May 13, 2024.","Delgado will oversee Avanos' global supply chain operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226185,"accession_number":"0001606498-24-000055","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q1 2024 results; key figures not available in 8-K","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced results for three months ended March 31, 2024.","No specific EPS, revenue, or guidance figures included in filing text or exhibit.","Investors should refer to the full press release for detailed financial data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":166100000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226184,"accession_number":"0001606498-24-000053","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avanos Medical stockholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors: Gary Blackford, Lisa Egbuonu-Davis, Patrick O'Leary, Julie Shimer, Joseph Woody; each received over 39M votes for.","Ratified Deloitte & Touche as independent auditor for 2024 with 42.5M votes for vs 435k against.","Advisory vote on NEO compensation approved with 38.5M votes for, 2.1M against, and 2.3M broker non-votes.","About 93% of outstanding shares represented (42.99M shares) at the April 25, 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245251,"accession_number":"0001606498-24-000016","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical Q4 net sales $173.3M (-4.6% YoY); 2024 outlook $685-$705M revenue, adj. EPS $1.30-$1.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.","Q4 GAAP diluted EPS $0.24 (vs $0.21); adjusted EPS $0.36 (vs $0.45). Full-year GAAP loss $(0.21) (vs $0.46 EPS); adjusted EPS $1.03 (vs $1.00).","Free cash flow for 2023 was $14.6M, down from $71.6M in 2022; Q4 outflow $3.4M.","Completed sale of respiratory health business (Oct 2) and acquired Diros Technology (July 24) to focus on Pain Management and Digestive Health.","2024 guidance: net sales $685-$705M (organic growth 3%-6%), adj. gross margin 59.5%-60.5%, adj. diluted EPS $1.30-$1.45."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":673300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245250,"accession_number":"0001606498-24-000002","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical issues preliminary Q4/FY2023 results; no figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Announced selected unaudited preliminary results for Q4 and full year ended Dec 31, 2023.","Press release furnished as Exhibit 99.1 but actual financial data is not included in filing text.","No specific revenue, EPS, or guidance numbers disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":673300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}